UltraGreen secures $188 M strategic investment from 65 Equity Partners, Vitruvian Partners

The $188 million strategic investment was signed Monday by UltraGreen.ai (UltraGreen), a Singapore-based provider of precision healthcare solutions and fluorescence-guided surgical technologies, under the leadership of Vitruvian Partners (Vitruvian) and 65 Equity Partners (65EP).

August Global Partners (August) also participated in the round, according to a statement from UltraGreen.

It stated that the investment will support UltraGreen’s next stage of growth and shows a strong belief in the company’s surgical imaging platform driven by artificial intelligence (AI).

As the largest supplier of Indocyanine Green (ICG), known as IC-Green in the US and Verdye abroad, UltraGreen dominates the Fluorescence Guided Surgery (FGS) market through its Diagnostic Green business.

Worldwide, ICG is utilized in over 90% of FGS procedures.

“We are delighted to welcome 65EP, Vitruvian and August as shareholders of UltraGreen.ai. This investment marks their confidence in our mission to democratize precision surgery
worldwide and enables us to leverage their deep strategic expertise in scaling healthcare technologies across global markets,

“Their backing validates our vision of making data-driven surgical intelligence the standard of care in operating rooms worldwide. We believe the investment also aligns seamlessly with our strategic expansion and diversification, particularly in Asia,” said Ravi Sajwan, Founder and Chief Executive Officer of UltraGreen.ai.

The statement claims that UltraGreen’s ability to integrate ICG agents, cutting-edge imaging equipment, and proprietary AI quantification software into its fluorescence ecosystem is strengthened by its collaboration with 65EP, Vitruvian, and August.

These technologies are being used more and more in high-value procedures, such as robotic, minimally invasive, and colorectal surgery, where they assist surgeons in more accurately visualizing anatomy and assessing perfusion.

UltraGreen helps improve outcomes for patients and surgeons by covering the entire surgical workflow, from visualization to quantification to decision support.

“This investment via our Anchor Fund aligns strategically with our mandate of supporting high quality, high growth businesses,

“UltraGreen is the global leader in precision surgical solutions, and Singapore is a key location from which it can expand into the Asia Pacific region, where there are significant growth opportunities,” said Francis Woo, Chief Corporate Officer and Managing Director at 65EP.

UltraGreen’s leadership in fluorescence-guided surgery is already revolutionizing clinical practice globally, according to Richard Chen, Cortex Partner at Vitruvian.